FDA approves new CAR-T competitor to Gilead’s Tecartus
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...
emjreviews.com2h
BMS, Gilead and Sanofi lead Q3 market cap growth
Gilead Sciences, seeing a 22% boost ... bolstered by the still high demand for their weight-loss and diabetes drugs, which ...
Gilead Sciences: Approaching Overvalued
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
FiercePharma4h
Autolus readies its CAR-T Aucatzyl to go after heavy hitter competition following FDA nod
Watch out, Gilead and Novartis: there's a new CAR-T in town. Autolus is ready to hit the ground running after winning FDA approval for its Aucatzyl, a late entry to the heated CD19 CAR-T cell therapy ...
'Life changing' blood cancer drugs approved by NHS for aggressive form of disease
Aileen Lamb, from Edinburgh who had acute myeloid leukaemia said the approval of the new drug gives sufferers hope.